Skip to main content

Table 2 Baseline characteristics of patients claiming > 5 and < 5 bromocriptine prescriptions

From: Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine

Variable  > 5 claimed bromocriptine percriptions (n = 603)  < 5 claimed bromocriptine percriptions(n = 2432) p-value
Age at onset (year) 35.0 [28.7, 44.5] 31.3 [27.6, 35.5]  < 0.0001
Comorbidities, n (%)    
Ischemic heart disease 7 (1.2) 13 (0.5) 0.16
Acute myocardial infarction  ≤ 3 (NA)  ≤ 3 (NA) NA
Atrial fibrillation 5 (0.8)  ≤ 3 (NA) NA
Ischemic stroke 7 (1.2) 8 (0.3) 0.02
Transient ischemic attack 4 (0.7)  ≤ 3 (NA) NA
Embolism 0 (0.0) 0 (0.0) NA
Pulmonary embolism 0 (0.0) 4 (0.2) 0.71
Deep vein thrombosis  ≤ 3 (NA) 13 (0.5) NA
Atherosclerosis 6 (1.0) 0 (0.0)  < 0.0001
Coagulopathy  ≤ 3 (NA) 4 (0.2) NA
Hypertension 41 (6.8) 34 (1.4)  < 0.0001
Diabetes 18 (3.0) 24 (1.0) 0.0004
Diagnosis of alcohol misuse 15 (2.5) 38 (1.6) 0.17
Chronic obstructive lung disease 8 (1.3) 13 (0.5) 0.07
Malignancy 18 (3.0) 19 (0.8)  < 0.0001
Chronic renal disease 5 (0.8) 11 (0.5) 0.41
Abnormal liver function 6 (1.0) 8 (0.3) 0.07
Medication, n (%)    
Beta-blockers 34 (5.6) 48 (2.0)  < 0.0001
Calcium channel blockers 19 (3.2) 19 (0.8)  < 0.0001
RAS inhibitors 20 (3.3) 18 (0.7)  < 0.0001
Vasodilators 0 (0.0) 0 (0.0) NA
Antiadrenergic drugs  ≤ 3 (NA) 6 (0.2) NA
Thiazides 45 (7.5) 39 (1.6)  < 0.0001
Loop diuretics 26 (4.3) 31 (1.3)  < 0.0001
Spironolactone 7 (1.2) 4 (0.2) 0.001
Diuretics, combination 7 (1.2) 5 (0.2) 0.003
Digoxin 0 (0.0) 6 (0.2) 0.48
Statins 12 (2.0) 6 (0.2)  < 0.0001
Antidiabetics 22 (3.6) 33 (1.4) 0.0003
Aspirin 18 (3.0) 15 (0.6)  < 0.0001
ADP inhibitors 0 (0.0) 0 (0.0) NA
Anticoagulants  ≤ 3 (NA)  ≤ 3 (NA) NA
  1. p-values were obtained by chi-square test for comparison
  2. IQR Interquartile range
  3. Pharmaceuticals: Claimed prescription within 366 days before baseline date
  4. RAS Renin-Angiotensin system